S&P 500   3,939.43 (-1.49%)
DOW   33,583.39 (-1.07%)
QQQ   280.90 (-2.34%)
AAPL   142.34 (-2.93%)
MSFT   244.67 (-2.21%)
META   114.07 (-6.83%)
GOOGL   96.65 (-2.84%)
AMZN   88.33 (-2.94%)
TSLA   179.30 (-1.73%)
NVDA   158.60 (-4.52%)
NIO   13.16 (+2.81%)
BABA   91.00 (+0.53%)
AMD   69.65 (-5.39%)
T   19.08 (+1.76%)
MU   53.42 (-1.15%)
CGC   3.59 (-16.90%)
F   13.24 (-1.05%)
GE   84.85 (+0.22%)
DIS   92.11 (-3.98%)
AMC   6.74 (-9.53%)
PYPL   71.86 (-2.39%)
PFE   49.50 (-2.42%)
NFLX   304.36 (-2.63%)
S&P 500   3,939.43 (-1.49%)
DOW   33,583.39 (-1.07%)
QQQ   280.90 (-2.34%)
AAPL   142.34 (-2.93%)
MSFT   244.67 (-2.21%)
META   114.07 (-6.83%)
GOOGL   96.65 (-2.84%)
AMZN   88.33 (-2.94%)
TSLA   179.30 (-1.73%)
NVDA   158.60 (-4.52%)
NIO   13.16 (+2.81%)
BABA   91.00 (+0.53%)
AMD   69.65 (-5.39%)
T   19.08 (+1.76%)
MU   53.42 (-1.15%)
CGC   3.59 (-16.90%)
F   13.24 (-1.05%)
GE   84.85 (+0.22%)
DIS   92.11 (-3.98%)
AMC   6.74 (-9.53%)
PYPL   71.86 (-2.39%)
PFE   49.50 (-2.42%)
NFLX   304.36 (-2.63%)
S&P 500   3,939.43 (-1.49%)
DOW   33,583.39 (-1.07%)
QQQ   280.90 (-2.34%)
AAPL   142.34 (-2.93%)
MSFT   244.67 (-2.21%)
META   114.07 (-6.83%)
GOOGL   96.65 (-2.84%)
AMZN   88.33 (-2.94%)
TSLA   179.30 (-1.73%)
NVDA   158.60 (-4.52%)
NIO   13.16 (+2.81%)
BABA   91.00 (+0.53%)
AMD   69.65 (-5.39%)
T   19.08 (+1.76%)
MU   53.42 (-1.15%)
CGC   3.59 (-16.90%)
F   13.24 (-1.05%)
GE   84.85 (+0.22%)
DIS   92.11 (-3.98%)
AMC   6.74 (-9.53%)
PYPL   71.86 (-2.39%)
PFE   49.50 (-2.42%)
NFLX   304.36 (-2.63%)
S&P 500   3,939.43 (-1.49%)
DOW   33,583.39 (-1.07%)
QQQ   280.90 (-2.34%)
AAPL   142.34 (-2.93%)
MSFT   244.67 (-2.21%)
META   114.07 (-6.83%)
GOOGL   96.65 (-2.84%)
AMZN   88.33 (-2.94%)
TSLA   179.30 (-1.73%)
NVDA   158.60 (-4.52%)
NIO   13.16 (+2.81%)
BABA   91.00 (+0.53%)
AMD   69.65 (-5.39%)
T   19.08 (+1.76%)
MU   53.42 (-1.15%)
CGC   3.59 (-16.90%)
F   13.24 (-1.05%)
GE   84.85 (+0.22%)
DIS   92.11 (-3.98%)
AMC   6.74 (-9.53%)
PYPL   71.86 (-2.39%)
PFE   49.50 (-2.42%)
NFLX   304.36 (-2.63%)
CVE:RX

BioSyent - RX Stock Forecast, Price & News

C$7.03
-0.17 (-2.36%)
(As of 12/6/2022 03:17 PM ET)
Add
Compare
Today's Range
C$7.03
C$7.03
50-Day Range
C$6.56
C$7.86
52-Week Range
C$6.24
C$10.00
Volume
200 shs
Average Volume
4,950 shs
Market Capitalization
C$85.06 million
P/E Ratio
14.35
Dividend Yield
2.22%
Price Target
C$8.00
RX stock logo

About BioSyent (CVE:RX) Stock

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Receive RX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter.

RX Stock News Headlines

BioSyent Initiates First Dividend
BioSyent reports Q2 results
BioSyent Releases Q2 and H1 2022 Financial Results
BioSyent Announces Adoption of Dividend Policy
See More Headlines
Receive RX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter.

RX Company Calendar

Last Earnings
5/25/2017
Today
12/06/2022
Next Earnings (Estimated)
3/08/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$8.00
High Stock Price Forecast
C$8.00
Low Stock Price Forecast
C$8.00
Forecasted Upside/Downside
+13.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$27.68 million
Cash Flow
C$2.24 per share
Book Value
C$2.71 per share

Miscellaneous

Free Float
N/A
Market Cap
C$85.06 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. René C. Goehrum (Age 63)
    Chairman, CEO & Pres
    Comp: $542.38k
  • Mr. Robert J. March
    VP of Fin. & CFO
  • Mr. Joost van der Mark
    VP of Corp. Devel.
  • Ms. Neelu Atwal
    Director of HR
  • Mr. Alfred D'Souza
    Advisor













RX Stock - Frequently Asked Questions

Should I buy or sell BioSyent stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioSyent in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RX shares.
View RX analyst ratings
or view top-rated stocks.

What is BioSyent's stock price forecast for 2023?

2 analysts have issued 12 month price targets for BioSyent's shares. Their RX share price forecasts range from C$8.00 to C$8.00. On average, they expect the company's stock price to reach C$8.00 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price.
View analysts price targets for RX
or view top-rated stocks among Wall Street analysts.

How have RX shares performed in 2022?

BioSyent's stock was trading at C$8.26 at the beginning of 2022. Since then, RX stock has decreased by 14.9% and is now trading at C$7.03.
View the best growth stocks for 2022 here
.

When is BioSyent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our RX earnings forecast
.

How were BioSyent's earnings last quarter?

BioSyent Inc. (CVE:RX) released its earnings results on Thursday, May, 25th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.02. The firm earned $3.82 million during the quarter, compared to analyst estimates of $4.80 million.

Is BioSyent a good dividend stock?

BioSyent (CVE:RX) pays an annual dividend of C$0.16 per share and currently has a dividend yield of 2.22%. The dividend payout ratio is 32.65%. This payout ratio is at a healthy, sustainable level, below 75%.

What other stocks do shareholders of BioSyent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSyent investors own include Aurora Cannabis (ACB), Canadian National Railway (CNR), Bank of Nova Scotia (BNS), Cross Timbers Royalty Trust (CRT), Dollarama (DOL), Enbridge (ENB), Gilead Sciences (GILD), National Bank of Canada (NA) and Air Canada (AC).

What is BioSyent's stock symbol?

BioSyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How do I buy shares of BioSyent?

Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BioSyent's stock price today?

One share of RX stock can currently be purchased for approximately C$7.03.

How much money does BioSyent make?

BioSyent (CVE:RX) has a market capitalization of C$85.06 million and generates C$27.68 million in revenue each year.

How can I contact BioSyent?

BioSyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The official website for the company is www.biosyent.com. The company can be reached via phone at +1-905-2060013.

This page (CVE:RX) was last updated on 12/6/2022 by MarketBeat.com Staff